Lenvatinib
ACCRU-ITOG-1504
Phase 2 small_molecule completed
Quick answer
Lenvatinib for Columnar Cell Variant Thyroid Gland Papillary Carcinoma is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed